Cite
Gupta VG, Hirst J, Petersen S, et al. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gynecol Oncol. 2021;162(1):163-172doi: 10.1016/j.ygyno.2021.04.015.
Gupta, V. G., Hirst, J., Petersen, S., Roby, K. F., Kusch, M., Zhou, H., Clive, M. L., Jewell, A., Pathak, H. B., Godwin, A. K., Wilson, A. J., Crispens, M. A., Cybulla, E., Vindigni, A., Fuh, K. C., & Khabele, D. (2021). Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gynecologic oncology, 162(1), 163-172. https://doi.org/10.1016/j.ygyno.2021.04.015
Gupta, Vijayalaxmi G, et al. "Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer." Gynecologic oncology vol. 162,1 (2021): 163-172. doi: https://doi.org/10.1016/j.ygyno.2021.04.015
Gupta VG, Hirst J, Petersen S, Roby KF, Kusch M, Zhou H, Clive ML, Jewell A, Pathak HB, Godwin AK, Wilson AJ, Crispens MA, Cybulla E, Vindigni A, Fuh KC, Khabele D. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gynecol Oncol. 2021 Jul;162(1):163-172. doi: 10.1016/j.ygyno.2021.04.015. Epub 2021 Apr 16. PMID: 33867143; PMCID: PMC8647995.
Copy
Download .nbib